Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study

Table 6

Dermatology Life Quality Index (DLQI) score (mean (SD)).

	Dose group (%)
	0.5% (N=8)	1.0% (N=9)	2.0% (N=8)	4.0% (N=8)	Vehicle (N=7)	Total (N=40)
Day 8	-0.4 (2.67)	0.9 (1.54)	-1.4 (2.50)	2.1 (2.75)	2.3 (2.63)	0.7 (2.70)
Day 15	-0.4 (3.50)	1.3 (2.55)	-0.1 (2.47)	0.9 (3.18)	0.7 (4.03)	0.5 (3.06)
P value	1.0	0.5	0.0313	0.2813	0.5313	0.7258
Day 22	-0.3 (3.37)	0.5 (3.55)	-0.3 (1.67)	1.4 (3.25)	1.4 (3.87)	0.5 (3.13)
P value	0.9375	0.7188	0.125	0.375	0.625	0.9731
Day 28	-0.6 (4.37)	1.1 (3.27)	0.8 (2.38)	1.4 (2.92)	2.3 (3.68)	0.9 (3.34)
P value	1.0	0.8125	0.0313	0.4688	0.7188	0.3367

, compared with the DLQI score at day 8.